EGFR and non-small cell lung carcinoma: In summary, we provide new evidence that P.A is useful in the treatment of EGFR-mutant NSCLC cell lines and displays a different treatment mechanism in these cell lines compared with non-EGFR-mutant NSCLC cell lines.